

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

**SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults:  
a prospective cohort study**

Andrew G. Letizia\*, Yongchao Ge\*, Sindhu Vangeti\*, Carl Goforth\*, Dawn L Weir\*, Natalia A. Kuzmina, Hua Wei Chen, Dan Ewing, Alessandra Soares-Schanoski, Mary-Catherine George, William D. Graham, Franca Jones, Preeti Bharaj, Rhonda A. Lizewski, Stephen A. Lizewski, Jan Marayag, Nada Marjanovic, Clare Miller, Sagie Mofsowitz, Venugopalan D. Nair, Edgar Nunez, Danielle M. Parent, Chad K. Porter, Ernesto Santa Ana, Megan Schilling, Daniel Stadlbauer, Victor Sugiharto, Michael Termini, Peifang Sun, Russell. P. Tracy, Florian Krammer, Alexander Bukreyev, Irene Ramos, Stuart C. Sealfon

\*Contributed equally

**Naval Medical Research Center, Silver Spring, MD USA** (A G Letizia MD, C Goforth PhD, D L Weir PhD, H W Chen PhD, D Ewing BS, W D Graham PhD, F Jones PhD, J Marayag BA, E Nunez AS, C K Porter PhD, E Santa Ana AS, M Schilling PhD, V Sugiharto PhD, P Sun PhD)

**Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY USA** (Y Ge PhD, S Vangeti PhD, M-C George PhD, N Marjanovic MS, C Miller PhD, S Mofsowitz BS, V D Nair PhD, A Soares-Schanoski PhD, I Ramos PhD, S C Sealfon MD)

**Department of Pathology University of Texas Medical Branch and Galveston National Laboratory, Galveston, TX USA** (P Bharaj PhD, N A Kuzmina PhD, A Bukreyev PhD)

**Naval Medical Research Unit SIX, Lima Peru** (R A Lizewski MD, S A Lizewski PhD)

**Department of Pathology & Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT USA** (D M Parent BS, R P Tracy PhD)

**Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA** (D Stadlbauer PhD, F Krammer PhD)

**Naval Medical Readiness and Training Command Beaufort, Beaufort, SC USA** (M Termini MD)

Correspondence to: Dr. Stuart C. Sealfon Icahn School of Medicine at Mount Sinai, Annenberg 14-44, One Gustave L. Levy Place, New York, NY 10029 USA

## 41 **Summary**

42 **Background:** The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subsequent  
43 infection among seropositive young adults was studied prospectively.

44 **Methods:** The study population comprised 3,249 predominantly male, 18-20-year-old Marine recruits.  
45 Upon arrival at a Marine-supervised two-week quarantine, participants were assessed for baseline SARS-  
46 CoV-2 IgG seropositivity, defined as a 1:150 dilution or greater on receptor binding domain and full-  
47 length spike protein enzyme-linked immunosorbent (ELISA) assays. SARS-CoV-2 infection was assessed  
48 by PCR at initiation, middle and end of the quarantine. After appropriate exclusions, including  
49 participants with a positive PCR during quarantine, we performed three biweekly PCR tests in both  
50 seropositive and in seronegative groups once recruits left quarantine and entered basic training and  
51 baseline neutralizing antibody titers on all subsequently infected seropositive and selected seropositive  
52 uninfected participants.

53 **Findings:** Among 189 seropositive participants, 19 (10.1%) had at least one positive PCR test for SARS-  
54 CoV-2 during the six-week follow-up (1.1 cases per person-year). In contrast, 1,079 (48.0%) of the 2,247  
55 seronegative participants tested positive (6.2 cases per person-year). The incidence rate ratio was 0.18  
56 (95% CI 0.11-0.28,  $p < 0.00001$ ). Among seropositive recruits, infection was associated with lower  
57 baseline full-length spike protein IgG titers ( $p < 0.0001$ ). Compared with seronegative recruits,  
58 seropositive recruits had about 10-fold lower viral loads (ORF1ab gene,  $p < 0.005$ ), and trended towards  
59 shorter duration of PCR positivity ( $p = 0.18$ ) and more frequent asymptomatic infections ( $p = 0.13$ ). Among  
60 seropositive participants, baseline neutralizing titers were detected in 45 of 54 (83.3%) uninfected and in  
61 6 of 19 (31.6%) infected participants during the 6 weeks of observation (ID<sub>50</sub> difference  $p < 0.0001$ ).

62 **Interpretation:** Seropositive young adults had about one-fifth the risk of subsequent infection compared  
63 with seronegative individuals. Although antibodies induced by initial infection are largely protective, they  
64 do not guarantee effective SARS-CoV-2 neutralization activity or immunity against subsequent infection.  
65 These findings may be relevant for optimization of mass vaccination strategies.

66 **Funding:** Defense Health Agency and Defense Advanced Research Projects Agency  
67  
68  
69

## 70 **Introduction**

71 As of mid-December 2020, more than 72 million severe acute respiratory syndrome coronavirus 2  
72 (SARS-CoV-2) infections have been diagnosed world-wide<sup>1</sup>. Serological surveys indicate that the actual  
73 number of infections has been many times higher than the cumulative incidence of diagnosed cases, with  
74 seropositivity rates approaching 10% in some countries and more than 40% in the Brazilian Amazon<sup>2-4</sup>.  
75 With the onset of mass SARS-CoV-2 vaccination programs and the increasing proportion of previously  
76 infected individuals, the risk of reinfection after natural infection is an important question for modeling  
77 the pandemic, estimating herd immunity and guiding vaccination strategies<sup>5,6</sup>.

78 Most individuals mount a sustained serologic response after initial infection<sup>7-11</sup>. Similar to the  
79 response to other coronaviruses, the production of IgG antibodies against SARS-CoV-2 peaks several  
80 weeks after infection, goes through a decline phase and then stabilizes. The overall humoral response to  
81 SARS-CoV-2 is highly variable among individuals<sup>9</sup>. SARS-CoV-2 specific IgG antibodies can be  
82 detected in serum from most individuals several months after infection<sup>11</sup>. However, a percentage of  
83 infected patients, ranging from 2.5% to 28% in different studies, do not maintain detectable circulating  
84 antibodies<sup>9</sup> or neutralizing activity<sup>10-12</sup> at later time points. About 10% of individuals who developed  
85 antibodies to SARS-CoV-2, all of whom had full-length spike protein-specific IgG antibody titers lower  
86 than 1:320, failed to develop measurable neutralizing activity<sup>11</sup>.

87 Reports have established that SARS-CoV-2 reinfection occurs after previous infection as well as  
88 in seropositive individuals<sup>13-22</sup>. Several studies have reported that SARS-CoV-2 IgG antibodies<sup>22,23</sup> and  
89 neutralizing antibodies<sup>24</sup> provide protection against subsequent infection. The initial trial results of the  
90 adenoviral vector-based SARS-CoV-2 vaccine, ChAdOx1 nCoV-19 (AZD1222), noted that among the  
91 373 participants who were seropositive at baseline, 3 (0.8%) had subsequent positive swab PCR tests; in  
92 comparison, among 11,263 baseline seronegative participants in all arms of that study, 218 (1.9%)  
93 developed a positive test<sup>21</sup>. A study of SARS-CoV-2 serological status and infection among healthcare  
94 workers identified 2 infections among 1265 (0.16%) who were seropositive and 223 among 11,364  
95 (2.0%) who were seronegative<sup>22</sup>. Young adults, of whom a high proportion are asymptotically infected  
96 and become seropositive in the absence of known infection<sup>25,26</sup> can be an important source of transmission

97 to more vulnerable populations<sup>27</sup>. Evaluating the protection against subsequent SARS-CoV-2 infection  
98 conferred by seropositivity in young adults is important for determining the need for vaccinating  
99 previously infected individuals in this age group.

100 We utilized the COVID-19 Health Action Response for Marines (CHARM) study<sup>26</sup>, a  
101 longitudinal prospective cohort study, to examine the effect of SARS-CoV-2 seropositivity on the risk of  
102 developing SARS-CoV-2 infection in young, healthy adult Marine recruits.

103

## 104 **Methods**

### 105 **Study design and participants**

106 The prospective study observation period began when Marine recruits arrived at Marine Corps  
107 Recruit Depot – Parris Island (MCRDPI) to commence basic training (Figure 1). To mitigate the spread of  
108 SARS-CoV-2, just before transferring to MCRDPI, the United States Marine Corps (USMC)  
109 implemented two separate quarantine protocols. The first was a two-week home quarantine. After that,  
110 the recruits traveled, while masked and socially distanced, to a second USMC-supervised quarantine  
111 situated at either a college campus from May until July 2020 or at a hotel from August until October  
112 2020. The supervised quarantine employed extensive public health measures, as previously described<sup>26</sup>,  
113 that were strictly enforced by US Marine instructors at all times. The recruits and staff were forbidden to  
114 leave, and no visitors other than deliveries of supplies and food along with local essential workers and the  
115 study staff were allowed onto the premises. At the end of this quarantine period, the USMC required all  
116 recruits to test negative for SARS-CoV-2 by PCR before proceeding to MCRDPI to initiate basic training.

117 Within 48 hours of arriving at the supervised quarantine location, recruits were offered the  
118 opportunity to volunteer for CHARM. Recruits were eligible if they were  $\geq 18$  years of age. Since recruits  
119 are a vulnerable population and at risk for coercion, special measures were undertaken including study  
120 briefers, who are active-duty Navy personnel wore civilian clothes, did not disclose military ranks, did not  
121 have members in the recruit's chain of command present, and ensured that participation would not affect  
122 a recruit's medical care or influence the grading of a recruit's military performance by superiors.

123 Institutional Review Board approval was obtained from the Naval Medical Research Center (protocol  
124 number NMRC.2020.0006) in compliance with all applicable U.S. federal regulations governing the  
125 protection of human subjects. All participants provided written informed consent.

126 At enrollment, participants completed a questionnaire consisting of demographic information,  
127 risk-factors, reporting of 14 specific COVID-19 related symptoms or any other unspecified symptom, and  
128 brief medical-history. At quarantine weeks 0, 1 and 2 a mid-turbinate nares swab for SARS-CoV-2 PCR  
129 testing and sera were obtained and questionnaire administered. The follow up questionnaire inquired  
130 about the same COVID-19 related symptoms since the last study visit.

131 Participants who had three negative swab PCR results at the beginning, middle and end of  
132 quarantine and a baseline serum serology test at the beginning of the supervised quarantine that identified  
133 them as seronegative or seropositive for SARS-CoV-2 according to criteria described below were  
134 followed prospectively. At weeks 2, 4 and 6 after transfer from the quarantine location to MCRDPI, a  
135 mid-turbinate nares swab for SARS-CoV-2 PCR testing and sera were obtained and the symptom  
136 questionnaire administered. When clinically indicated due to the development of symptoms, some  
137 participants were evaluated at the MCRDPI clinic and diagnosed by rapid testing. If positive, they went to  
138 the isolation barracks, where the study team was able to follow up and repeat testing outside of the  
139 scheduled longitudinal follow up encounters. Participants without PCR results obtained during the  
140 MCRDPI study period were excluded from analysis.

141

## 142 **Procedures**

### 143 **SARS-CoV-2 quantitative PCR testing**

144 All swabs in viral transport media (VTM) were kept at 4°C. All assays were performed within 48h  
145 of sample collection at high complexity Clinical Laboratory Improvement Amendments (CLIA)-certified  
146 laboratories using the US FDA authorized ThermoFisher TaqPath™ COVID-19 Combo Kit (Thermo Fisher  
147 Scientific, Waltham MA). Lab24Inc (Boca Raton, FL) performed PCR testing from study initiation until  
148 the end of July, and the Naval Medical Research Center (Silver Spring, MD) from August until the  
149 conclusion of the study.

## 150 **SARS-CoV2 enzyme-linked immunosorbent assay (ELISA)**

151           The presence and levels of IgG SARS-CoV-2-specific antibodies in serum were determined using  
152 an enzyme-linked immunosorbent assay (ELISA) as previously described<sup>26</sup>. Briefly, 384-well Immulon 4  
153 HBX plates (ThermoFisher), or 96-well half area Microlon plates (Greiner Bio-One), were coated  
154 overnight at 4°C with recombinant his-tagged spike (S) receptor binding domain (S-RBD)  
155 (SinoBiological) or full-length spike protein (LakePharma) at a concentration of 2 µg/ml in phosphate-  
156 buffered saline (PBS). Plates were washed three times with 0.1% Tween-20 (Fisher Scientific) in PBS  
157 (PBS-T) using an automated ELISA plate washer (Aquamax 4000, Molecular devices), and blocked for 1  
158 h at room temperature (RT) with 3% milk (BioRad) PBS-T. Blocking solution was removed, and serum  
159 samples diluted in 1% milk PBS-T were dispensed in the wells. At least 2 positive controls (sera with  
160 known IgG presence), 8 negative controls (sera collected before July 2019) and 4 blanks (no serum) were  
161 included in every assay. Plates were incubated for 2 h at room temperature, and then washed 3 times with  
162 PBS-T. Next, peroxidase conjugated goat F(ab')<sub>2</sub> Anti-Human IgG (Abcam) was added at a dilution  
163 1:5,000-1:10,000 dilutions (determined after optimization for each antibody lot) in 1% milk PBS-T, and  
164 plates were incubated for 1 h at room temperature. Plates were washed 6 times with PBS-T, developed  
165 using o-Phenylenediamine (Sigma), and the reaction was stopped after 10 min with 3M HCl. Optical  
166 density (OD) at 492 nm was measured using a microplate reader (SpectramaxM2, Molecular Devices).  
167 All serum samples were screened at a 1:50 dilution with S-RBD. Those samples with an OD 492 nm  
168 value higher than the average of the negative controls plus 3 times their standard deviation (SD) in the  
169 screening assay underwent titration assay (6 serial 1:3 serum dilutions starting at 1:50) using both S-RBD  
170 and full-length spike protein. Serum samples were considered positive for each assay when at least 2  
171 consecutive dilutions showed higher OD 492 nm than the average of the negative controls plus 3 times  
172 their SD at the correspondent dilution or 0.15 OD 492 nM. Specificity was 100% on both S-RBD and  
173 full-length spike protein ELISA using 70 control sera obtained before July 2019. Participants were only  
174 considered seropositive to SARS-CoV-2 if IgG titrations for both ELISA gave a positive result at a  
175 minimum of 1:150 dilution.

176

## 177 **Neutralization assays**

178 Two-fold serial dilutions of heat-inactivated serum at an initial dilution of 1:20, were prepared in serum  
179 free media (Minimum Essential Medium; Thermo fisher Scientific, Cat No. 11095080 containing 25 mM  
180 HEPES and 0.05 g/L gentamicin sulfate) and incubated with an equal volume of mNeonGreen SARS-  
181 CoV-2<sup>28</sup> for 1 hour at 37°C at a final concentration of 200 plaque forming units in humidified 5% CO<sub>2</sub>.  
182 Virus-serum mixtures were then added to Vero-E6 monolayers in 96 well optical black plates and  
183 incubated at 37°C. Plates were read using the BioTek Cytation 5 plate reader (EX 485 nm, EM 528 nm) at  
184 24 h post-infection. Following background signal correction, neutralization titers at a fluorescent end  
185 point of 50% virus reduction (ID<sub>50</sub>) were determined.

186

## 187 **Statistical Analysis**

188 Analyses, figures and tables were generated using R 3.6.3. Race was categorized as non-  
189 Hispanic white, non-Hispanic black, non-Hispanic other, and Hispanic. Cochran-Armitage Chi-  
190 square test for trend was used to compare proportions testing positive for SARS-CoV-2 by  
191 increasing titers. Cumulative incidence rates computed by Kapan-Meir method were used to  
192 estimate the risk of SARS-CoV-2 infection between seropositive and seronegative participants  
193 and also between different titers among the seropositive participants. Observational follow-up  
194 began upon arrival at MCRDPI and participants were censored at the first observed positive  
195 PCR, or at the latest time with valid PCR assay or at the termination of the study (6 weeks of  
196 observation). The Cox proportional hazards model controlled for age, sex and race. The p-values  
197 from the cumulative incidence curves were determined by the log-rank test and the p-value and  
198 CI for Cox proportional hazard model was computed by the R function coxph. The cycle  
199 threshold (Ct) values of viral genes were quantile normalized to remove the batch effects  
200 between Lab24Inc and Naval Medical Research Center laboratory assays. The CI and p-values for  
201 comparing the mean of the Ct values for two groups are computed based on the two sample t-  
202 test.

## 203 **Role of the Funding Source**

204 The funders had no role in the design of the protocol, data collection, data management, data analysis,  
205 data interpretation, or writing of the report. SCS, AGL, YG, CP and IR had access to all deidentified data.  
206 SCS and AGL had final responsibility for the decision to submit for publication.

207

## 208 **Results**

209 The flow of participants through the study is shown in Figure 1. Two weeks before the initiation  
210 of basic training and the start of the prospective cohort study period, a total of 3,249 out of 4,657 eligible  
211 new Marine recruits (70%) enrolled in CHARM and underwent a supervised two-week quarantine.  
212 Exclusions before the prospective study period included 73 participants who were SARS-CoV-2 PCR  
213 positive on at least one of the three PCR tests performed during quarantine, 53 who lacked baseline  
214 serology results and 47 who were lost to follow-up.

215 Of the remaining 3,076 participants, 225 were baseline seropositive, having SARS-CoV-2 IgG  
216 titers in serum samples obtained at the beginning of quarantine that were greater than 1:150 both with S-  
217 RBD and with full-length spike protein ELISA, and 2,851 were baseline seronegative. Among the  
218 seropositive participants, 36 (16.0%) were excluded from analysis due either to being lost to follow up  
219 (n=34), or to lacking valid PCR results during the study period (n=2). In the seronegative group, 604  
220 (21.2%) participants were excluded due to either being lost to follow up (n=532), or lacking valid PCR  
221 results (n=72). Participants were lost to follow up for specific reasons unknown to the study team,  
222 including dropping out of the study, being separated from the Marines or being removed from the base for  
223 medical or administrative reasons. Demographic characteristics of the two groups in the study cohort are  
224 shown in Table 1. Most participants were 18-20 years old and male. The two groups were well-balanced  
225 with the exception of a higher proportion of participants who self-identified as Hispanic and as black in  
226 the seropositive group.

227 A total of 19 out of 189 (10.1%, 1.1 cases per person-year) seropositive participants and 1,079 out  
228 of 2,247 (48.0%, 6.2 cases per person-year) seronegative participants had at least one positive SARS-  
229 CoV-2 PCR result during the six-week study period, representing an 0.18 (95% CI: 0.11 to 0.28, p<0.001)

230 incidence rate ratio for SARS-CoV-2 infections in the seropositive group (Table 2). The temporal  
231 incidence of infection in seropositive and seronegative groups is shown in Figure 2A. After adjusting the  
232 effects of race, age and sex on the SARS-CoV-2 infections, the hazard ratio comparing seropositive  
233 participants and seronegative participants was 0.16 (95% CI, 0.10-0.25,  $p < 0.001$ ; supplementary Table 1).

234 Within the seropositive group, we assessed the association between the SARS-CoV-2 IgG  
235 baseline titers and the risk of infection. As shown in Figure 2B, supplementary Figure 2 and Table 3, we  
236 found a strong association between subsequent PCR positive infection and lower titers of IgG antibodies  
237 directed to full-length spike protein ( $p < 0.0001$ ) as well as to S-RBD ( $p = 0.0019$ ). The detailed Cox  
238 proportional hazard analysis in supplementary Table 1 gives a hazard ratio of 0.45 (95% CI 0.32-0.65,  
239  $p < 0.001$ ) and 0.67 (95% CI 0.47-0.96,  $p = 0.028$ ) respectively for the full-length spike protein titer and S-  
240 RBD titer, both log-transformed.

241 We examined baseline SARS-CoV-2 IgG neutralizing antibody activity in all seropositive  
242 participants who became PCR positive during the observation period and in the first 54 participants who  
243 were seropositive but remained PCR negative. Neutralizing activity was above the limit of detection in 45  
244 of 54 (83.3%) seropositive participants who never became PCR positive and in 6 of 19 (31.6%) of  
245 participants infected during the 6 weeks of observation. The neutralizing activity assessed as 50%  
246 inhibitory dose (ID<sub>50</sub>) was significantly higher in the participants who did not become PCR positive  
247 during the study ( $p < 0.0001$ , Cochran-Armitage test, Table 3, supplementary Figure 2).

248 We also compared virus loads estimated by PCR Ct values between the seronegative and  
249 seropositive PCR infected groups and found that seronegative individuals had on average 4, 2.6 and 3.3  
250 lower cycle values for ORF1ab gene ( $p = 0.004$ , 95% CI 1.23 to 6.67), S gene ( $p = 0.11$ , 95% CI -0.58 to  
251 5.77) and N gene ( $p = 0.033$ , 95% CI 0.27 to 6.33), respectively, than seropositive individuals. The lower  
252 Ct values suggest an approximately 10-fold higher virus load in the samples from seronegative  
253 participants (Table 4). In addition, seronegative participants tended to have a longer duration of PCR  
254 positivity than seropositive individuals ( $p = 0.18$ ). The proportion of asymptomatic participants was 84.2%  
255 (16 of 19) and 67.8% (732 of 1079) in seropositive and seronegative infected individuals, respectively, a  
256 difference that did not reach significance ( $p = 0.13$ ).

257

## 258 **Discussion**

259           This study of primarily young, male Marine recruits found that the presence of antibodies to  
260 SARS-CoV-2 conferred an 82% reduced incidence rate of SARS-CoV-2 infection. The percentage of  
261 symptomatic infections was comparable in seropositive and seronegative participants. Among the  
262 seropositive group, the participants that became infected had lower antibody titers than those that were  
263 uninfected, and were more likely to lack detectable baseline neutralizing antibody activity. Our results  
264 indicate that although antibodies induced by infection are largely protective, they do not guarantee  
265 effective immunity against subsequent infection.

266           This study leveraged a two-week USMC-mandated quarantine period during which baseline  
267 SARS-CoV-2 antibody status was established on arrival. Only baseline seronegative or seropositive  
268 participants who had multiple negative SARS-CoV-2 PCR tests during the supervised quarantine were  
269 included in the prospective study. The three negative PCR tests during quarantine helped ensure that  
270 infections diagnosed during basic training were not persistent infections but incident infection occurring  
271 during the prospective period. The two-week home quarantine preceding the supervised quarantine, as  
272 well as the relatively low frequency of infections diagnosed on arrival and during quarantine, further  
273 support that only incident infections were included in our analyses. The aggregate infection rate in both  
274 groups during the six weeks of observation at MCRDPI was 1,098 out of 2,436 (45.1%) participants. In  
275 contrast, only 28 of 3,249 (0.9%) participants were PCR positive on arrival at the supervised quarantine  
276 and less than 2% of participants became PCR positive during the two-week quarantine period. In view of  
277 the consecutive two periods of quarantine, the relatively low rate of infection during quarantine, and the  
278 three consecutive negative PCR tests, it is unlikely that any participants with persistent infection  
279 preceding their arrival at MCRDPI were entered into the prospective study. Even if this occurred, such  
280 cases would be unlikely to affect the relative risk calculations comparing the seropositive and  
281 seronegative groups. This methodology allowed for the creation of two well defined groups who entered  
282 basic training without active infection and differed primarily by baseline serology.

283 The two groups had similar demographic profiles, with the exception of a slightly higher  
284 prevalence in self-identified Hispanic and non-Hispanic black participants in the seropositive group. The  
285 seropositive group was almost 50% Hispanic and 22% non-Hispanic black participants compared to 22%  
286 and 12%, respectively in the seronegative group. This is likely due to minority populations having higher  
287 seroprevalence rates during the COVID-19 pandemic in general and among young adults specifically<sup>27</sup>.

288 Rates of infection and the risk reduction provided by seropositivity are important for  
289 understanding transmission dynamics for COVID-19, for epidemiologic modeling, and for estimating and  
290 achieving herd immunity levels, a major goal of mass vaccination strategies. Herd immunity is difficult to  
291 predict if the infection risk after natural and vaccine-induced immunity is unknown. Since SARS-CoV-2  
292 vaccines may not provide sterile immunity, it is possible that both previously infected and vaccinated  
293 individuals may later become infected. It is not known if either can contribute to transmission events. We  
294 found only a modest, approximately 10-fold decrease in nares virus load as estimated by swab PCR Ct  
295 levels in the seropositive compared with the seronegative infected participants. This finding suggests that  
296 some reinfected individuals could have a similar capacity to transmit infection as those who are infected  
297 for the first time. The rate at which reinfection occurs after vaccines and natural immunity are important  
298 for estimating the percentage of the population that needs to be vaccinated to suppress the pandemic.

299 The crowded living conditions, demanding regimen and requirement for personal contact during  
300 basic training despite the pandemic leads not only to an increased risk for respiratory epidemics<sup>29</sup>, but also  
301 potentially to higher exposure levels. The close quarters and constant contact among recruits that are  
302 needed for team building allows a viral infection to rapidly proliferate within a unit. The physically and  
303 mentally demanding training environment may also suppress immunity. These conditions may contribute  
304 to the high infection rate we observed during the six-week study period. These factors are not typically  
305 present in the civilian community. Therefore, the study setting limits the generalizability of our findings  
306 to other settings where the frequency and intensity of exposure and the susceptibility of the host might  
307 differ.

308 The clinical outcomes between seropositive and seronegative groups were similar, with the  
309 majority (84.2% and 67.8%, respectively) being asymptomatic. The two groups did not show a significant

310 difference in the duration of PCR positivity. No participants in either group needed inpatient care.  
311 Although our findings are limited to healthy young adults, studying this population does have the  
312 advantage of reducing the confounding factors of age and co-morbid illnesses<sup>30</sup>. Infection in seropositive  
313 participants was associated with lower SARS-CoV-2 IgG titers and absent or lower levels of neutralizing  
314 antibody activity. Young adults have high rates of asymptomatic and pauci-symptomatic infection, which  
315 has been associated with lower levels of antibodies and potentially a less robust immune memory  
316 response. This could lead to higher overall rates of re-infection among this population compared to other  
317 populations. We did not examine the role of cell mediated immunity or host, environment and virus  
318 factors leading to reinfection.

319         Since the study population is a fairly accurate representation of the races and ethnicities in the US  
320 population among 18-20-year-olds, the results are most applicable to young male adults. The relative risk  
321 of infection may be different in seropositive females and in adults of other ages or health status. Other  
322 limitations in our study include not being able to investigate the exposure event during a seropositive  
323 participant's initial infection prior to arrival at quarantine, the inability to confirm initial SARS-CoV-2  
324 infection by PCR in the seropositive group, and potentially missing detectable infections that occurred  
325 between biweekly sampling.

326         Our investigation is likely to underestimate the risk of SARS-CoV-2 infection in previously  
327 infected individuals because the seronegative group includes an unknown number of previously infected  
328 participants who did not have significant IgG titers in their baseline serum sample. Despite this  
329 underestimation, we found that previously infected participants identified by seropositivity are susceptible  
330 to repeat infection, with nearly one-fifth the incidence rate of those without evidence of previous  
331 infection. This suggests that COVID-19 vaccination may be necessary for control of the pandemic in  
332 previously infected young adults.

333

#### 334 **Contributors**

335 AGL, IR, and SCS provided overall leadership and guidance to the investigation. YG performed  
336 statistical analysis and data curation. SV, CKP, CG, DLW, RL, and IR contributed to data analysis. RL,

337 JM, EN, ESA, SM, NM, contributed to sample collection and management. CG, DLW, WDG contributed  
338 to data collection. SV, NAK, DE, AS, PB, NM, CM, DMP, SM, DS, PS performed serological assays.  
339 HWC, and VS performed PCR assays. AGL, SV, DLW, NAK, AS, RL, CM, CKP, MT, and IR  
340 contributed to data interpretation. AGL, CG, FJ, RL, EN supervised sample collection. AGL, CG, RL  
341 supervised data collection. RPT, FK, AB, and IR supervised serology assays. MS supervised PCR assays.  
342 MG and MT provided project administration and coordination. YG, SV, IR, CKP and VDN prepared  
343 figures. AGL, YG, SV, IR and SCS wrote and revised the original draft. All authors reviewed and  
344 approved the final manuscript.

345

#### 346 **Declaration of Interests**

347 AGL, YG, SV, CG, DLW, HWC, DE, MCG, WDG, FJ, RL, JM, NM, CM, SM, VDN, EN, CKP, ESA,  
348 ASS, MS, VS, MT, PS, RPT, IR and SCS declare no competing interests. DP owned stock in Co-  
349 Diagnostics Inc during the conduct of the study. DP held stock in Co-Diagnostics, Inc. DS and FK have  
350 filed a patent regarding serological assays and for SARS-CoV-2 and Icahn School of Medicine at Mount  
351 Sinai has founded a company to commercialize serological assays they developed. AGL, CG, DLW,  
352 HWC, DEW, DG, FJ, JM, EN, CKP, ESA, MS, VS, PS, RAL, SAL, and MT are military Service  
353 members or GS employees. This work was prepared as part of their official duties. Title 17, U.S.C., §105  
354 provides that copyright protection under this title is not available for any work of the U.S. Government.  
355 Title 17, U.S.C., §101 defines a U.S. Government work as a work prepared by a military Service member  
356 or employee of the U.S. Government as part of that person's official duties. The views expressed in the  
357 article are those of the authors and do not necessarily express the official policy and position of the US  
358 Navy, the Department of Defense, the US government or the institutions affiliated with the authors.

359

#### 360 **Acknowledgements**

361

362 We thank Quanterix (Billerica, MA) for providing beta-level serological assay kits used for ELISA  
363 validation studies; Mary Anne Amper, Nitish Seenarine, Mital Vasoya, Illya Aronskyy and Braian Qela  
364 for outstanding technical assistance; German Nudelman and Stas Rirak for database development; Celia  
365 Gelernter and Adam B. Sealfon for editing assistance; Mitchel Rabinowitz for project management; Terri

366 Brantley and Andrea Gates for administrative support; Adam Armstrong for strategic guidance; the many  
367 US Navy corpsmen who assisted in the logistics and sample acquisition; and the devoted Marine recruits  
368 who volunteered for this study. This work received funding from the Defense Health Agency through the  
369 Naval Medical Research Center (9700130) and from the Defense Advanced Research Projects Agency  
370 (contract number N6600119C4022).  
371

372 **Table and Figure legends**

373 **Table 1: Demographic characteristics of participants studied prospectively in the seropositive and**  
374 **seronegative groups.** A total of 120 participants are excluded due to being lost to follow up, lacking any  
375 baseline valid IgG or becoming PCR positive during the quarantine period. The table includes all 3,076  
376 participants who entered training and were followed prospectively, including the 640 participants who  
377 were later excluded for further analysis

378

379 **Table 2: Comparison of SARS-Cov-2 infection (PCR positive) at MCRDPI between the seropositive**  
380 **and seronegative groups.** The analysis is based on the 2,436 participants who had valid PCR data  
381 obtained during the prospective follow-up period.

382

383 **Table 3. SARS-CoV-2 S-RBD and full-length spike IgG titers and neutralizing antibody activity in**  
384 **PCR positive and PCR negative seropositive participants.** p-values were assessed by the Cochran-  
385 Armitage test. ID50 is the titer at which a 50% reduction in virus infection was observed.

386

387 **Table 4: Comparison of symptoms and cycle threshold values between SARS-CoV-2 infected (PCR**  
388 **positive) seropositive and seronegative groups.**

389

390 **Figure 1: Flow chart of the study design and outcomes.** The baseline analyses were performed within  
391 two days of enrollment and two weeks before the prospective study period. Nearly all participants were  
392 tested at scheduled biweekly intervals during the prospective study period. A few participants were  
393 diagnosed by the MCRDPI clinic, and were tested by the study team at times not corresponding to the  
394 regularly scheduled longitudinal follow ups. Participants lost to follow up either dropped out of the study,  
395 were separated from the Marine Corps or were removed from the base for medical or administrative  
396 reasons. The study team did not know the reason for participants missing study visits.

397

398 **Figure 2: SARS-CoV-2 PCR positive incidence curves during the six-week follow-up period. A.**  
399 Overall cumulative incidence for testing PCR positive in the baseline seropositive and seronegative  
400 groups. B. Cumulative incidence for testing PCR positive in the seropositive group at different baseline  
401 full-length spike protein IgG titers which ranged from 1:150 to 1:12150. The charts are derived from  
402 Kaplan-Meier survival analyses and the cumulated censored participants are listed.  
403  
404  
405  
406  
407

408 **References**

- 409 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in  
410 real time. *Lancet Infect Dis* 2020; **20**(5): 533-4.
- 411 2. Buss LF, Prete CA, Jr., Abraham CMM, et al. Three-quarters attack rate of SARS-CoV-2  
412 in the Brazilian Amazon during a largely unmitigated epidemic. *Science* 2020.
- 413 3. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain  
414 (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet* 2020;  
415 **396**(10250): 535-44.
- 416 4. Stadlbauer D, Tan J, Jiang K, et al. Repeated cross-sectional sero-monitoring of SARS-  
417 CoV-2 in New York City. *Nature* 2020.
- 418 5. Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-  
419 19 protective immunity. *Lancet* 2020; **395**(10236): 1527-9.
- 420 6. Overbaugh J. Understanding protection from SARS-CoV-2 by studying reinfection. *Nat*  
421 *Med* 2020; **26**(11): 1678-9.
- 422 7. Beaudoin-Bussieres G, Laumaea A, Anand SP, et al. Decline of Humoral Responses  
423 against SARS-CoV-2 Spike in Convalescent Individuals. *mBio* 2020; **11**(5).
- 424 8. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-  
425 CoV-2 in Iceland. *N Engl J Med* 2020; **383**(18): 1724-34.
- 426 9. Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 Antibodies  
427 After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network -  
428 12 States, April-August 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(47): 1762-6.
- 429 10. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing  
430 antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat*  
431 *Microbiol* 2020; **5**(12): 1598-607.

- 432 11. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2  
433 infection persist for months. *Science* 2020; **370**(6521): 1227-30.
- 434 12. Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of neutralizing antibody titers in  
435 the months after SARS-CoV-2 infection. *J Infect Dis* 2020.
- 436 13. Chan PKS, Lui G, Hachim A, et al. Serologic Responses in Healthy Adult with SARS-  
437 CoV-2 Reinfection, Hong Kong, August 2020. *Emerg Infect Dis* 2020; **26**(12): 3076-8.
- 438 14. Huang J, Zheng L, Li Z, et al. Kinetics of SARS-CoV-2 positivity of infected and  
439 recovered patients from a single center. *Sci Rep* 2020; **10**(1): 18629.
- 440 15. Lee JS, Kim SY, Kim TS, et al. Evidence of Severe Acute Respiratory Syndrome  
441 Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019. *Clin Infect Dis*  
442 2020.
- 443 16. Lu J, Peng J, Xiong Q, et al. Clinical, immunological and virological characterization of  
444 COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. *EBioMedicine* 2020; **59**:  
445 102960.
- 446 17. Mulder M, van der Vegt D, Oude Munnink BB, et al. Reinfection of SARS-CoV-2 in an  
447 immunocompromised patient: a case report. *Clin Infect Dis* 2020.
- 448 18. Munoz Mendoza J, Alcaide ML. COVID-19 in a patient with end-stage renal disease on  
449 chronic in-center hemodialysis after evidence of SARS-CoV-2 IgG antibodies. Reinfection or  
450 inaccuracy of antibody testing. *IDCases* 2020; **22**: e00943.
- 451 19. Selhorst P, Van Ierssel S, Michiels J, et al. Symptomatic SARS-CoV-2 reinfection of a  
452 health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody  
453 response. *Clin Infect Dis* 2020.
- 454 20. Van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2  
455 reinfection by a phylogenetically distinct strain. *Clin Infect Dis* 2020.

- 456 21. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-  
457 19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled  
458 trials in Brazil, South Africa, and the UK. *The Lancet* 2020.
- 459 22. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-  
460 CoV-2 Infection in Health Care Workers. *New England Journal of Medicine* 2020.
- 461 23. Harvey RA, Rassen JA, Kabelac CA, et al. Real-world data suggest antibody positivity to  
462 SARS-CoV-2 is associated with a decreased risk of future infection. *medRxiv* 2020:  
463 2020.12.18.20248336.
- 464 24. Addetia A, Crawford KHD, Dingens A, et al. Neutralizing Antibodies Correlate with  
465 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack  
466 Rate. *J Clin Microbiol* 2020; **58**(11): e02107-20.
- 467 25. Letizia AG, Ge Y, Goforth CW, et al. SARS-CoV-2 seropositivity among US Marine  
468 recruits *Emerging Infectious Diseases* 2021; **revision awaiting decision**.
- 469 26. Letizia AG, Ramos I, Obla A, et al. SARS-CoV-2 Transmission among Marine Recruits  
470 during Quarantine. *N Engl J Med* 2020; **383**(25): 2407-16.
- 471 27. De Sanctis V, Ruggiero L, Soliman AT, Daar S, Di Maio S, Kattamis C. Coronavirus  
472 Disease 2019 (COVID-19) in adolescents: An update on current clinical and diagnostic  
473 characteristics. *Acta Biomed* 2020; **91**(2): 184-94.
- 474 28. Xie X, Muruato A, Lokugamage KG, et al. An Infectious cDNA Clone of SARS-CoV-2.  
475 *Cell Host Microbe* 2020; **27**(5): 841-8 e3.
- 476 29. Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC. Respiratory diseases  
477 among U.S. military personnel: countering emerging threats. *Emerg Infect Dis* 1999; **5**(3): 379-  
478 85.
- 479 30. Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses  
480 to influenza infection and vaccination. *Immun Ageing* 2020; **17**(1): 37.

481

Label	Levels	Seropositive	Seronegative	Total
Total N (%)		225 (7.3)*	2851 (92.7)	3076
Age	Mean (SD)	19.0 (1.8)†	19.1 (1.9)	19.1 (1.9)
Sex	F	22 (9.8)	229 (8.0)	251 (8.2)
	M	203 (90.2)	2622 (92.0)	2825 (91.8)
Race	Non-Hispanic White	56 (24.9)	1698 (59.6)	1754 (57.0)
	Non-Hispanic Black	50 (22.2)	349 (12.2)	399 (13.0)
	Non-Hispanic Other	7 (3.1)	183 (6.4)	190 (6.2)
	Hispanic	112 (49.8)	621 (21.8)	733 (23.8)
Non-US residence	No	216 (96.0)	2749 (96.4)	2965 (96.4)
	Yes	4 (1.8)	19 (0.7)	23 (0.7)
	N/A‡	5 (2.2)	83 (2.9)	88 (2.9)
Non-US birth	No	189 (84.0)	2626 (92.1)	2815 (91.5)
	Yes	32 (14.2)	192 (6.7)	224 (7.3)
	N/A	4 (1.8)	33 (1.2)	37 (1.2)

482 **Table 1: Demographic characteristics of participants studied prospectively in the seropositive and**  
 483 **seronegative groups.** A total of 120 participants were excluded due to being lost to follow up, lacking  
 484 any baseline valid IgG or becoming PCR positive during the quarantine period. The table includes all  
 485 3,076 participants who entered training and were followed prospectively, including the 640 participants  
 486 who were later excluded for further analysis (see Figure 1).

487 \* The continuous variable age is summarized with mean (SD)

488 † Categorical variables are summarized with counts (percentages)

489 ‡ If a participant answered unknown or left a question blank, then the value is grouped into “N/A”.

490

491

Group	Seropositive	Seronegative
Total	189	2247
PCR positive	19	1079
Incidence proportion (%)	10.1	48
Proportion difference (%)	-38 (-45 to -31, p<0.001)	
Observed person year	17.1	175.2
Incidence rate	1.11	6.16
Incidence rate ratio	0.18 (0.11 to 0.28, p<0.001)	

492

493

494

495

496

497

**Table 2: Comparison of SARS-Cov-2 infection (PCR positive) at MCRDPI between the seropositive and seronegative groups.** The analysis is based on the 2,436 participants who had valid PCR data obtained during the prospective follow-up period.

Assay	Group	N	No. (%) of people at the titer or ID50 interval					mean±sem	p-value
titer			150	450	1350	4050	12150		
S-RBD	PCR+	19	5(26.3)	5(26.3)	6(31.6)	3(15.8)	0(0)	674.5±181.1	0.017
	PCR-	170	6(3.5)	49(28.8)	81(47.6)	27(15.9)	7(4.1)	1186.3±86.2	
Full-length spike protein	PCR+	19	6(31.6)	2(10.5)	2(10.5)	6(31.6)	3(15.8)	1202.6±472.7	1.20E-05
	PCR-	170	3(1.8)	2(1.2)	41(24.1)	83(48.8)	41(24.1)	3723.7±259.9	
ID50 range			<20	[20,40)	[40,80)	[80,160)	[160,320)		
Neutralization	PCR+	19	13(68.4)	2(10.5)	3(15.8)	1(5.3)	0(0)	16.8±3.1*	9.80E-05
	PCR-	54	9(16.7)	10(18.5)	19(35.2)	15(27.8)	1(1.9)	48.2±5.7	

498

499

500

501

502

503

504

**Table 3. SARS-CoV-2 S-RBD and full-length spike IgG titers and neutralizing antibody activity in PCR positive and PCR negative seropositive participants.** p-values were assessed by the Cochran-Armitage test. ID50 is the titer at which a 50% reduction in virus infection was observed.

\*The mean and SEM is computed after converting undetectable titer <20 to be 10.

Total N	Seropositive	Seronegative	Difference comparison
	<b>19</b>	<b>1079</b>	
Infection duration>7 days	6 (31.6%)*	510 (47.3%)	-0.16 (-0.38 to 0.07, p=0.175)†
Symptomatic	3 (15.8%)	347 (32.2%)	-0.16 (-0.38 to 0.05, p=0.129)
N gene Ct	27.7 (7.6) ‡	24.4 (5.5)	3.30 (0.27 to 6.33, p=0.033) ¶
S gene Ct	26.9 (7.1)	24.3 (5.3)	2.60 (-0.58 to 5.77, p=0.109)
ORF1ab Ct	28.0 (7.0)	24.0 (5.3)	3.95 (1.23 to 6.67, p=0.004)

505

506

507

508

509

510

511

512

513


**Table 4: Comparison of symptoms and cycle threshold values between SARS-CoV-2 infected (PCR positive) seropositive and seronegative groups.**

\* Binary variables are summarized with counts (percentages)


† Difference in proportion for binary variables

‡ The cycle threshold (Ct) values of three viral genes are summarized by mean (SD)

¶ Difference in mean for the Ct values



514  
 515 **Figure 1: Flow chart of the study design and outcomes.** The baseline analyses were performed within  
 516 two days of enrollment and two weeks before the prospective study period. Nearly all participants were  
 517 tested at scheduled biweekly intervals during the prospective study period. A few participants were  
 518 diagnosed by the Marine Corps Recruit Depot Parris Island clinic, and were tested by the study team at  
 519 times not corresponding to the regularly scheduled longitudinal follow ups. Participants lost to follow up  
 520 either dropped out of the study, were separated from the Marine Corps or were removed from the base for  
 521 medical or administrative reasons. The study team did not know the reason for participants missing study  
 522 visits.  
 523  
 524



525  
 526 **Figure 2: SARS-CoV-2 PCR positive incidence curves during the six-week follow-up period. A.**  
 527 Overall cumulative incidence for testing PCR positive in the baseline seropositive and seronegative  
 528 groups. B. Cumulative incidence for testing PCR positive in the seropositive group at different baseline  
 529 full-length spike protein IgG titers which ranged from 1:150 to 1:12150. The cumulative incidence rate is  
 530 computed by the Kaplan-Meier method, and the cumulated censored participants are listed.  
 531

532 **Supplementary Tables and Figures**

			<b>N</b>	<b>Hazard ratio (univariable)</b>	<b>Hazard ratio (multivariable)</b>
<b>Group Analysis*</b>	Group	Seronegative	2247	-‡	-
		Seropositive	189	0.16 (0.10-0.25, p<0.001)	0.16 (0.10-0.25, p<0.001)
	Age	Mean (SD)	19.1 (1.9)	0.97 (0.94-1.00, p=0.088)	0.97 (0.94-1.00, p=0.070)
	Sex	F	217	-	-
		M	2219	1.03 (0.85-1.25, p=0.746)	1.06 (0.87-1.29, p=0.541)
	Race	Non-Hispanic White	1352	-	-
		Non-Hispanic Black	324	0.75 (0.62-0.91, p=0.004)	0.86 (0.70-1.04, p=0.120)
		Non-Hispanic Other	162	0.97 (0.77-1.22, p=0.793)	0.96 (0.76-1.22, p=0.763)
Hispanic		598	0.94 (0.81-1.08, p=0.360)	1.08 (0.93-1.24, p=0.324)	
<b>S-RBD Titer Analysis†</b>					
Titer	Mean (SD)	10.1 (1.4)	0.67 (0.48-0.94, p=0.022)	0.67 (0.47-0.96, p=0.028)	
Age	Mean (SD)	19.0 (1.8)	1.00 (0.78-1.27, p=0.970)	1.00 (0.79-1.27, p=0.975)	
Sex	F	17	-	-	
	M	172	0.95 (0.22-4.10, p=0.941)	1.19 (0.25-5.55, p=0.829)	
Race	Non-Hispanic White	46	-	-	
	Non-Hispanic Black	45	0.68 (0.11-4.08, p=0.674)	0.59 (0.10-3.60, p=0.571)	
	Non-Hispanic Other	5	3.41 (0.35-32.83, p=0.288)	2.47 (0.23-26.67, p=0.456)	
	Hispanic	93	2.28 (0.65-7.98, p=0.199)	2.05 (0.58-7.25, p=0.268)	
<b>Full-Length Spike Protein Titer Analysis‡</b>					
Titer	Mean (SD)	8.1 (1.1)	0.49 (0.35-0.68, p<0.001)	0.45 (0.32-0.65, p<0.001)	
Age	Mean (SD)	19.0 (1.8)	1.00 (0.78-1.27, p=0.970)	1.04 (0.79-1.35, p=0.794)	
Sex	F	17	-	-	
	M	172	0.95 (0.22-4.10, p=0.941)	1.07 (0.19-6.22, p=0.936)	
Race	Non-Hispanic White	46	-	-	
	Non-Hispanic Black	45	0.68 (0.11-4.08, p=0.674)	0.68 (0.11-4.19, p=0.678)	
	Non-Hispanic Other	5	3.41 (0.35-32.83, p=0.288)	1.62 (0.11-23.89, p=0.724)	
	Hispanic	93	2.28 (0.65-7.98, p=0.199)	4.82 (0.79-10.11, p=0.112)	


533  
534 **Supplementary Table 1: Cox proportional hazard regression analysis of group and titer association**  
535 **with SARS-CoV-2 infection.**

536 \* The predictor in multivariable analysis includes predictor variables group, age, sex and race using all  
537 2,436 participants with valid PCR data to detect SARS-CoV-2 infection during the six-week  
538 prospective study period.

539 † The predictor in multivariable analysis includes predictor variables titer, age, sex and race using 189  
540 participants in the seropositive group. The titers (S-RBD and full-length spike protein) have been log  
541 transformed. The univariate analysis for both S-RBD titer and full-length spike protein titer gives the  
542 same results of age, sex and race due to use the same set of participants and were kept for both to make  
543 it is easier to compare the univariable and multivariable analysis.

544 ‡ The dashed symbol indicates the reference level against which other levels were compared.

545



546

547 **Supplementary Figure 1: SARS-CoV-2 PCR positive incidence curves at different baseline RBD**  
 548 **IgG titers during the six-week follow-up period.** Cumulative incidence for testing PCR positive in the  
 549 seropositive group at different baseline RBD IgG titers, which ranged from 1:150 to 1:12150. The  
 550 numbers at risk and cumulated censored participants are listed below the table.

551


552

553

554

555

556



557  
558 **Supplementary Figure 2: Baseline neutralizing antibodies in PCR+ and PCR- seropositive**  
559 **participants.** The baseline 50% inhibitory dose (ID50) was determined for all seropositive participants  
560 who became SARS-CoV-2 PCR positive during the subsequent six-week observation period and in the  
561 first 54 seropositive participants enrolled who did not test PCR positive. N.D. indicates no inhibition  
562 detected at a 1:20 dilution which was the lowest titer evaluated. P value was assessed by the Cochran-  
563 Armitage test.

564  
565

566  
567